FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type patients. BRAF and other RAS rare mutations have been suggested as additional potential biomarkers for anti-EGFR agents in metastatic colo-rectal cancer. The present study aims to demonstrate the feasibility and the activity of the first-line combination of the GONO-FOLFOXIRI regimen and Panitumumab in molecularly selected metastatic colo-rectal cancer patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Oncologico del Nord-Ovest
• Treatments: Antibodies, Monoclonal; Panitumumab

Criteria

Inclusion Criteria:

• Histologically confirmed colorectal adenocarcinoma;

• Availability of formalin-fixed paraffin embedded tumor block from primary or metastasis;

• KRAS and BRAF wild-type status of primary colorectal cancer or related metastasis;

• Unresectable and measurable metastatic disease according to RECIST criteria;

• Male or female, aged >/= 18 years and
• ECOG PS < 2 if aged < 71 years;

• ECOG PS = 0 if aged 71-75 years;

• Life expectancy of more than 3 months;

• Adequate haematological function: ANC ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L, Hb ≥ 9 g/dL;

• Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases < 5 x ULN);

• Serum creatinine ≤ 1.5 x ULN;

• Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse;

• At least 6 weeks from prior radiotherapy and 4 weeks from surgery;

• Written informed consent to experimental treatment and pharmacogenomic analyses;

• Magnesium ≥ lower limit of normal;

• Calcium ≥ lower limit of normal.

Exclusion Criteria:

• Prior palliative chemotherapy;

• Prior treatment with EGFR inhibitors;

• Symptomatic peripheral neuropathy ≥ 2 grade NCIC-CTG criteria;

• Presence or history of CNS metastasis;

• Active uncontrolled infections; active disseminated intravascular coagulation;

• Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix;

• Clinically significant cardiovascular disease, for example cerebrovascular accidents (CVA) (≤ 6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia;

• Fertile women (< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception;

• Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment;

• History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.